Muscarinic M1 Receptor Compound Treats Alzheimer Disease
Summary
USPTO published patent application US20260092052A1 for a nitrogen-containing heterocyclic compound functioning as a muscarinic M1 receptor positive allosteric modulator. The compound is intended for prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, and dementia with Lewy bodies. Inventors include Masami Yamada, Shinkichi Suzuki, Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, and Makoto Kamata. Application No. 19010914 was filed on January 6, 2025.
What changed
USPTO published patent application US20260092052A1 disclosing a novel nitrogen-containing heterocyclic compound represented by formula (I) as a cholinergic muscarinic M1 receptor positive allosteric modulator. The compound and its salts are claimed for therapeutic use in treating Alzheimer's disease, schizophrenia, pain, sleep disorders, Parkinson's disease dementia, and dementia with Lewy bodies. CPC classifications span multiple heterocyclic compound categories (C07D 405/14, C07D 401/06, C07D 471/04) and therapeutic uses (A61K 31/4035, A61K 31/55).\n\nThis is a routine patent application publication providing public notice of the invention. No immediate compliance actions are required. Pharmaceutical companies, biotechnology firms, and healthcare researchers monitoring the muscarinic receptor patent landscape may wish to review the claims for freedom-to-operate considerations. The application is pending examination and no regulatory compliance deadlines apply.
Archived snapshot
Apr 2, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
NITROGEN-CONTAINING HETEROCYCLIC COMPOUND
Application US20260092052A1 Kind: A1 Apr 02, 2026
Inventors
Masami YAMADA, Shinkichi SUZUKI, Takahiro SUGIMOTO, Minoru NAKAMURA, Hiroki SAKAMOTO, Makoto KAMATA
Abstract
The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity and useful as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies, and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. wherein each symbol is as described in the specification, or a salt thereof.
CPC Classifications
C07D 405/14 A61K 31/045 A61K 31/13 A61K 31/325 A61K 31/4035 A61K 31/4155 A61K 31/4406 A61K 31/4439 A61K 31/445 A61K 31/55 C07D 209/46 C07D 401/06 C07D 401/10 C07D 401/14 C07D 403/04 C07D 403/10 C07D 405/04 C07D 471/04
Filing Date
2025-01-06
Application No.
19010914
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.